Agenda - Day 1

There are no agenda items with this track

10:00 am

10:00 am

Networking

Networking

Enter Networking Lounge, Connect with Your Pharma Industry Colleagues

  • Get a good start on the day and make connections with industry leadership
  • Join “drop-in” roundtables on most topical issues
  • Schedule 1-2-1 video meetings with peers
  • Gather essential content at virtual exhibit booths

11:00 am

11:00 am

Setting Today’s Plan from your Host

Share key highlights of this event to map the current situation and help in ensuring YOUR success from today.

11:05 am

11:05 am

Opening Keynote Address

Position Your Company to Succeed with a Market Access Update and Valuable Insights on the Impact of COVID-19 on Healthcare

2020 has been a year like no other, with multiple factors both exerting pressure on clinical research and driving an increased demand for quality evidence. The temporary shutdown of many clinical research sites in response to COVID-19 is forcing the need to look at existing sources of data and maximize the insights from these rich resources. In addition, regulatory changes that are in motion are driving increased demand for clinically meaningful evidence, as stakeholders focus on optimizing real world effectiveness of therapies and are taking a more patient-centric approach to care. Develop an action plan to evaluate the strategic implications of ongoing change to help you:

  • Assess some of the impacts that COVID-19 has had on the life sciences industry in Canada and on market access trends
  • Learn from your peers by bringing forward your most pressing questions on the current market access landscape
  • Stay on top of the evolving nature of evidence generation

Fine-tune your market access strategy with insight on Covid-19 and answers to your biggest challenges

11:30 am

11:30 am

Panel Discussion

Strategies for Managing Through the Adjusted Timeline and Transition to Implementation of the New Pricing Guidelines

Given the uncertainties created by the change in implementation date to the new pricing guidelines, navigating the marketplace will be challenging. Fine-tune your pricing strategy as the new guidelines gain clarity. Take away a road map to help your organization with:

  • Strategies for product positioning and pricing
  • Insights about determining factors on whether medicines will be classified as Category I or Category II
  • Understanding what impact the current consultation process could have on the final guidelines and on your organization

Gain clarity on how to align your pricing strategies with the new PMPRB pricing guidelines as they emerge under the new implementation timeline

12:00 pm

12:00 pm

Panel Discussion

Streamlining the Path to Market: Regulatory Modernization – Is Canada a Land of Regulatory Obstacles or Opportunities?

The federal government has faced challenges in updating regulations to keep up with the modern changes to drug discovery and with market access.  The result could be viewed as an onerous regulatory burden or as regulatory clarity paving the way for future opportunities.  Take back to your team actionable insights about:

  • The benefits expected from the current federal regulatory modernization project
  • Whether perceived regulatory burdens can be alleviated or reduced
  • How greater clarity in updated regulations can translate into opportunities for market access

Learn how to reduce regulatory burden and leverage regulatory modernization into increased opportunities

12:30 pm

12:30 pm

Networking

Networking

Build Relationships, Network and Experience Unparalleled Peer-to-Peer Learning

Expand your network and engage in-depth learning with your peers. Take advantage of any format to further build your knowledge and networking base:

  • “Drop-in” virtual Roundtable chats with up to 15 fellow delegates
  • Cozy 3-4 person discussion
  • Engage in 1:1 video conversation with peers or vendors
  • Vendor solution roundtables

1:00 pm

1:00 pm

Keynote Address

Analyze the Impact of Changes to CADTH’s New Review Process

A number of changes have recently been made to the CADTH drug review process. Gain critical insight that will help you understand and analyse the impact of these changes for your company. Source intelligence to:

  • Better understand the information requirements for drug submissions to CADTH;
  • Adopt best practices to better manage your product submissions under the revised process;
  • Adopt an efficient approach to navigating through this new review process

 

Position your product for successful navigation through the revised review process

1:30 pm

1:30 pm

Industry Expert - Case Study

Gathering Real-world Evidence to Support Your Review Submission

Governments, players and healthcare’s other stakeholders are increasingly required to incorporate quality data to support their submissions for reimbursement.  Explore new approaches to using Real World Evidence to improve the value proposition your medicines bring to the decision process and to patients. Take away strategies to:

  • Enhance the efficacy of your medications on individual patient outcomes
  • Evaluate the impact on the health of the overall patient population for your medication
  • Partner with your stakeholders to access data

Prove and improve the value, efficacy and impact of your medications with RWE

1:50 pm

1:50 pm

Networking

Networking

Visit Virtual Booths, Source Content and Engage in Demos with Industry Experts

·         Pose your biggest questions to leading industry vendor experts through 1:1 video conversations or chat.
·         Experience a live demo and understand your options. Source leading-edge content from virtual booths.
·         Walk away satisfied with solutions to your biggest challenges.

2:10 pm

2:10 pm

Panel Discussion

Gain Insights into the Impact of the Increasing Use of Biosimilars for Patients and the Marketplace

Many consider that increasing the use of biosimilars is key to putting healthcare budgets on a more financially sustainable path.  Understand the implications and opportunities for your business of recent policy decisions to foster a greater market share for biosimilars.  Develop an action plan to:

  • Prepare and support patients in the event they need to switch to a biosimilar
  • Analyse the impact on your biosimilar strategy of international collaboration to increase biosimilar market share
  • Adapt your Canadian market access strategies with medical and public policy guidance

Inform your strategy for biosimilars with key public policy insights

2:50 pm

2:50 pm

Key Take-Aways and Summary of Day One from your Host

Hear the key solutions and take-aways from today’s sessions. Source a summary of actions points for you to implement. Learn about the key highlights and content for tomorrow.

3:00 pm

3:00 pm

Networking

Networking

Networking Extravaganza and Virtual Happy Hour!

  • Meet informally with fellow delegates in “Drop-in” virtual roundtable chats.
  • Engage in 1:1 video conversation with peers or vendors.
  • Connect with fellow delegates as “recommend matches” based on similar interests and business objectives.

 

3:30 pm

3:30 pm

Conference Day 1 Adjourns

Get the latest news

*Privacy Policy